Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Checkpoint inhibitors in pancreatic cancer

Research output: Contribution to journalReviewResearchpeer-review

  1. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Checkpoint inhibitors in breast cancer - Current status

    Research output: Contribution to journalReviewResearchpeer-review

  3. A systematic review of bevacizumab efficacy in breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Immune checkpoint inhibitors, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathways have shown remarkable potential in several types of cancer. In this review we summarize published and ongoing studies on checkpoint inhibitors in pancreatic cancer (PC).

METHODS: We conducted a systematic literature search using Medline and Embase up to November 2018; additional data from a search on clinicaltrials.gov were included. Endpoints of interest encompassed overall survival (OS), progression free survival (PFS) and response rates.

RESULTS: Full-length articles constituted a minority of included records. Furthermore, few patients were enrolled, and only few phase II studies were identified. Disappointing limited activity was demonstrated with single-agent checkpoint inhibitors in PC. A small number of studies on combination therapy showed promise with regards to response. But overall, PC patients treated with checkpoint inhibitors were not shown to elicit improvement in response rates or overall survival.

CONCLUSION: Checkpoint inhibition monotherapy has failed to elicit efficacy in patients with pancreatic cancer. Combination regimens including chemotherapy have shown initial promise, but these results need to be verified. Numerous studies on checkpoint inhibition in PC are ongoing.

Original languageEnglish
JournalCancer Treatment Reviews
Volume78
Pages (from-to)17-30
Number of pages14
ISSN0305-7372
DOIs
Publication statusPublished - Aug 2019

    Research areas

  • Animals, Antibodies, Monoclonal/therapeutic use, Antineoplastic Agents, Immunological/therapeutic use, Cell Cycle Checkpoints/drug effects, Genes, cdc, Humans, Pancreatic Neoplasms/drug therapy

ID: 59155859